19.89
前日終値:
$20.05
開ける:
$19.99
24時間の取引高:
2.23M
Relative Volume:
1.70
時価総額:
$1.74B
収益:
$23.38M
当期純損益:
$-155.22M
株価収益率:
-9.0822
EPS:
-2.19
ネットキャッシュフロー:
$-134.36M
1週間 パフォーマンス:
+5.69%
1か月 パフォーマンス:
+0.96%
6か月 パフォーマンス:
-27.30%
1年 パフォーマンス:
-44.43%
Ideaya Biosciences Inc Stock (IDYA) Company Profile
名前
Ideaya Biosciences Inc
セクター
電話
650-443-6209
住所
5000 SHORELINE CT, SUITE 300, SOUTH SAN FRANCISCO, CA
IDYA を他の銘柄と比較する
株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
---|---|---|---|---|---|---|
![]()
IDYA
Ideaya Biosciences Inc
|
19.89 | 1.65B | 23.38M | -155.22M | -134.36M | -2.19 |
![]()
ONC
Beone Medicines Ltd Adr
|
245.58 | 26.10B | 3.81B | -644.79M | -669.77M | -6.24 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
442.05 | 111.96B | 11.10B | -988.90M | -1.26B | -3.92 |
![]()
AKTX
Akari Therapeutics Plc Adr
|
1.35 | 42.96M | 0 | 0 | 0 | 0.00 |
![]()
VRNA
Verona Pharma Plc Adr
|
81.20 | 6.39B | 0 | -153.72M | -103.81M | -2.00 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
490.28 | 63.52B | 14.09B | 4.50B | 2.96B | 39.28 |
Ideaya Biosciences Inc Stock (IDYA) Upgrades & Downgrades
日付 | アクション | アナリスト | 評価の変更 |
---|---|---|---|
2024-11-18 | 開始されました | Stephens | Overweight |
2024-11-05 | ダウングレード | Leerink Partners | Outperform → Market Perform |
2024-10-24 | 開始されました | UBS | Buy |
2024-10-15 | 開始されました | Cantor Fitzgerald | Overweight |
2024-07-08 | 開始されました | Mizuho | Outperform |
2024-03-08 | 開始されました | BTIG Research | Buy |
2023-08-08 | 開始されました | SVB Securities | Outperform |
2023-05-24 | 開始されました | Goldman | Buy |
2023-04-24 | アップグレード | Stifel | Hold → Buy |
2023-03-23 | 開始されました | Berenberg | Buy |
2023-02-28 | 開始されました | RBC Capital Mkts | Outperform |
2022-12-28 | 開始されました | CapitalOne | Overweight |
2022-10-27 | 開始されました | Citigroup | Buy |
2022-08-15 | ダウングレード | Stifel | Buy → Hold |
2022-07-18 | 再開されました | Oppenheimer | Outperform |
2022-03-10 | アップグレード | Stifel | Hold → Buy |
2021-09-23 | 開始されました | Stifel | Hold |
2021-06-04 | 再開されました | Robert W. Baird | Outperform |
2021-03-11 | 開始されました | Guggenheim | Buy |
2020-10-07 | 開始されました | Wedbush | Outperform |
2020-09-01 | 開始されました | Northland Capital | Outperform |
2020-07-13 | アップグレード | JP Morgan | Neutral → Overweight |
2020-06-17 | 繰り返されました | H.C. Wainwright | Buy |
2020-04-06 | 開始されました | H.C. Wainwright | Buy |
2020-03-13 | 開始されました | ROTH Capital | Buy |
2019-10-17 | 開始されました | Oppenheimer | Outperform |
2019-09-10 | 開始されました | Robert W. Baird | Outperform |
2019-06-17 | 開始されました | Citigroup | Buy |
2019-06-17 | 開始されました | JP Morgan | Neutral |
2019-06-17 | 開始されました | Jefferies | Buy |
すべてを表示
Ideaya Biosciences Inc (IDYA) 最新ニュース
IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - Eastern Progress
Ideaya Biosciences announces inducement grants under Nasdaq listing rule - TipRanks
IDEAYA Biosciences (IDYA) Grants Stock Options to New Employees | IDYA Stock News - GuruFocus
IDEAYA Biosciences Expands Oncology Team with 664,600 Share Grant Worth Over $13M - Stock Titan
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Purchased by Nuveen Asset Management LLC - Defense World
IDEAYA Biosciences (NASDAQ:IDYA) Price Target Raised to $66.00 - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Receives $54.27 Consensus PT from Brokerages - Defense World
(IDYA) Proactive Strategies - news.stocktradersdaily.com
JP Morgan Raises Price Target for IDEAYA Biosciences (IDYA) | ID - GuruFocus
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Acquired by Ameriprise Financial Inc. - Defense World
BNP Paribas Financial Markets Buys 10,543 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Jane Street Group LLC Reduces Stake in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Bank of America Corp DE Acquires 41,390 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
January 2026 Options Now Available For IDEAYA Biosciences - Nasdaq
Ideaya Biosciences: Value Beyond Darovasertib With ADC Program IDE849 (NASDAQ:IDYA) - Seeking Alpha
(IDYA) Investment Analysis - news.stocktradersdaily.com
FY2025 EPS Estimates for IDYA Cut by Cantor Fitzgerald - Defense World
Stifel Financial Corp Sells 3,834 Shares of IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Dimensional Fund Advisors LP Has $8.91 Million Stock Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
16,769 Shares in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Acquired by Raymond James Financial Inc. - Defense World
Brokers Issue Forecasts for IDYA Q2 Earnings - Defense World
Leerink Partnrs Has Bullish Estimate for IDYA Q2 Earnings - Defense World
IDEAYA Biosciences Receives Fast Track Designation for IDE161 in a Second Indication for the Treatment of Pretreated, Advanced or Metastatic HR+, Her2-, BRCA1/2 mutant Breast Cancer - Barchart.com
Ideaya Biosciences (IDYA) Faces Market Reaction Following FDA Le - GuruFocus
IDEAYA Biosciences Reports Q1 2025 Financial Results - TipRanks
IDEAYA Biosciences (NASDAQ:IDYA) Shares Down 10.2% After Earnings Miss - Defense World
IDEAYA Biosciences, Inc. (NASDAQ:IDYA) Shares Bought by Mariner LLC - Defense World
IDEAYA Biosciences, Inc. Reports First Quarter 2025 Financial Results and Provides Business Update - The Malaysian Reserve
IDEAYA Gets FDA Clearance to Initiate Clinical Trial of Antibody Drug Conjugate Program in Solid Tumors - marketscreener.com
IDEAYA Biosciences Posts Q1 Net Loss; Cash Runway Extended Through 2029 - marketscreener.com
IDEAYA gets approval to begin trial for its antibody drug conjugate in solid tumors - Seeking Alpha
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a - GuruFocus
Ideaya Biosciences (IDYA) Achieves Major Milestones in Oncology Programs | IDYA Stock News - GuruFocus
Ideaya Biosciences (IDYA) Advances with FDA Approval for IDE849 Trial | IDYA Stock News - GuruFocus
IDEAYA Biosciences Announces US FDA IND-Clearance For IDE849, A Potential First-In-Class DLL3 TOP1 ADC, For A Phase 1 Study In Solid Tumors - marketscreener.com
FDA clears IDEAYA’s Phase 1 trial for new cancer drug By Investing.com - Investing.com South Africa
FDA clears IDEAYA’s Phase 1 trial for new cancer drug - Investing.com
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors - marketscreener.com
IDEAYA Biosciences Announces US FDA IND-Clearance for IDE849, a Potential First-in-Class DLL3 TOP1 ADC, for a Phase 1 Study in Solid Tumors – Company Announcement - Financial Times
Earnings Flash (IDYA) IDEAYA Biosciences Posts Q1 Net Loss $0.82, vs. FactSet Est of $0.66 Loss - marketscreener.com
IDEAYA Receives Fast Track Designation for Potential First-in-Class PARG Inhibitor, IDE161, for Treatment of Pretreated, Platinum-Resistant Advanced or Metastatic Ovarian Cancer Patients having tumors with BRCA1/2 Mutations - Barchart.com
IDEAYA Biosciences Announces Phase 2 Expansion of Darovasertib and Crizotinib Combination in GNAQ/11 Metastatic Cutaneous Melanoma - Barchart.com
Why IDEAYA Biosciences, Inc. (IDYA) is Among the Best Small Cap Stocks to Buy with the Biggest Upside Potential - Insider Monkey
IDEAYA Biosciences (IDYA) to Release Quarterly Earnings on Tuesday - Defense World
Top 11 Small Cap Stocks to Buy with Biggest Upside Potential - Insider Monkey
Trading (IDYA) With Integrated Risk Controls - news.stocktradersdaily.com
Invesco Ltd. Has $1.46 Million Holdings in IDEAYA Biosciences, Inc. (NASDAQ:IDYA) - Defense World
Nothing is Better Than Ideaya Biosciences Inc (IDYA) stock at the moment - Sete News
Ideaya Biosciences Inc (IDYA)’s Ratio Roundup: Key Metrics for Trailing Twelve Months - DWinneX
IDYA (Ideaya Biosciences Inc) has impressive results - uspostnews.com
Investing in Ideaya Biosciences Inc (IDYA): What You Must Know - knoxdaily.com
Ideaya Biosciences Inc (IDYA) 財務データ
収益
当期純利益
現金流量
EPS
大文字化:
|
ボリューム (24 時間):